NCT06171880View on ClinicalTrials.gov

To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JC-001 and JLP-1901

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

March 11, 2022

Study Completion Date

May 13, 2022

Conditions
Healthy Adult
Interventions
DRUG

JLP-1901

administration of JLP-1901

DRUG

JC-001(active comparator)

administration of JC-001(tenofovir)

Trial Locations (1)

13497

Bundang CHA university global clinical trials center Institutional Review Board, Gyeonggi-do

Sponsors
All Listed Sponsors
lead

Jeil Pharmaceutical Co., Ltd.

INDUSTRY

NCT06171880 - To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JC-001 and JLP-1901 | Biotech Hunter | Biotech Hunter